{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T09:51:09Z","timestamp":1773741069370,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2003,4,1]]},"DOI":"10.1038\/sj.jhh.1001543","type":"journal-article","created":{"date-parts":[[2003,4,24]],"date-time":"2003-04-24T17:03:24Z","timestamp":1051203804000},"page":"271-276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease"],"prefix":"10.1038","volume":"17","author":[{"given":"H","family":"Matsuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Saruta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,4,11]]},"reference":[{"key":"BF1001543_CR1","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1172\/JCI112528","volume":"77","author":"S Anderson","year":"1986","unstructured":"Anderson S, Rennke HG, Brenner BM . Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Chin Invest 1986; 77: 1993\u20132000.","journal-title":"J Chin Invest"},{"key":"BF1001543_CR2","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1056\/NEJM198512263132601","volume":"313","author":"Y Taguma","year":"1985","unstructured":"Taguma Y et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985; 313: 1617\u20131620.","journal-title":"N Engl J Med"},{"key":"BF1001543_CR3","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"326","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD . The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 326: 1456\u20131462.","journal-title":"N Engl J Med"},{"key":"BF1001543_CR4","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1056\/NEJM199604113341502","volume":"334","author":"G Maschio","year":"1996","unstructured":"Maschio G et al. AIPRI Study Group. effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939\u2013945.","journal-title":"N Engl J Med"},{"key":"BF1001543_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861\u2013869.","journal-title":"N Engl J Med"},{"key":"BF1001543_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851\u2013860.","journal-title":"N Engl J Med"},{"key":"BF1001543_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/ki.1993.279","volume":"44","author":"V Kon","year":"1993","unstructured":"Kon V, Fogo A, Ichikawa I . Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993; 44: 545\u2013550.","journal-title":"Kidney Int"},{"key":"BF1001543_CR8","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1681\/ASN.V10112272","volume":"10","author":"H Matsuda","year":"1999","unstructured":"Matsuda H et al. Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: role of intrarenal bradykinin. J Am Soc Nephrol 1999; 10: 2272\u20132282.","journal-title":"J Am Soc Nephrol"},{"key":"BF1001543_CR9","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/NEJM199810293391804","volume":"339","author":"JV Gainer","year":"1998","unstructured":"Gainer JV et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998; 339: 1285\u20131292.","journal-title":"N Engl J Med"},{"key":"BF1001543_CR10","first-page":"R1090","volume":"271","author":"HM Siragy","year":"1996","unstructured":"Siragy HM, Jaffa AA, Margolius HS, Carey RM: Renin\u2013angiotensin system modulates renal bradykinin production. Am J Physiol 1996; 271: R1090\u2013R1095.","journal-title":"Am J Physiol"},{"key":"BF1001543_CR11","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1161\/hc3601.094304","volume":"104","author":"M Nishimoto","year":"2001","unstructured":"Nishimoto M et al. Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation. Circulation 2001; 104: 1274\u20131279.","journal-title":"Circulation"},{"key":"BF1001543_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1053\/ajkd.2001.25176","volume":"38","author":"D Russo","year":"2001","unstructured":"Russo D et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001; 38: 18\u201325.","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 4","key":"BF1001543_CR13","first-page":"S12","volume":"18","author":"H Tokuyama","year":"2000","unstructured":"Tokuyama H et al. Role of intrarenal angiotensin II (AII) and cyclooxygenase (COX)-1\/2 in chronic ischemic nephropathy. J Hypertens 2000; 18 (Suppl 4): S12.","journal-title":"J Hypertens"},{"key":"BF1001543_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0304-3940(94)90073-6","volume":"176","author":"K Ohta","year":"1994","unstructured":"Ohta K et al. A novel in vivo assay system for consecutive measurement of brain nitric oxide production combined with the microdialysis technique. Neurosci Lett 1994; 176: 165\u2013168.","journal-title":"Neurosci Lett"},{"key":"BF1001543_CR15","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1172\/JCI119360","volume":"99","author":"Y-H Liu","year":"1997","unstructured":"Liu Y-H et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997; 99: 1926\u20131935.","journal-title":"J Clin Invest"},{"key":"BF1001543_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1046\/j.1365-201x.2000.00660.x","volume":"168","author":"RM Carey","year":"2000","unstructured":"Carey RM, Jin X, Wang Z, Siragy HM . Nitric oxide: a physiological mediator of the type 2 (AT2) angiotensin receptor. Acta Physiol Scand 2000; 168: 65\u201371.","journal-title":"Acta Physiol Scand"},{"key":"BF1001543_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2369-3-2","volume":"3","author":"L Adler","year":"2002","unstructured":"Adler L et al. Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-B, and nitrite excretion. BMC Nephrol 2002; 3: 2.","journal-title":"BMC Nephrol"},{"key":"BF1001543_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0014-2999(01)01357-7","volume":"428","author":"M Rahma","year":"2001","unstructured":"Rahma M et al. Effects of furosemide on the tubular reabsorption of nitrates in anesthetized dogs. Eur J Pharmacol 2001; 428: 113\u2013119.","journal-title":"Eur J Pharmacol"},{"key":"BF1001543_CR19","doi-asserted-by":"publisher","first-page":"4S40","DOI":"10.1038\/sj.jhh.1000986","volume":"14","author":"B Sosa-Canache","year":"2000","unstructured":"Sosa-Canache B, Cierco M, Gutierrez CI, Israel A . Role of bradykinin and nitric oxide in the AT2 receptor-mediated hypotension. J Hum Hypertens 2000; 14: 4S40\u20134S46.","journal-title":"J Hum Hypertens"},{"key":"BF1001543_CR20","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1161\/01.HYP.35.5.1074","volume":"35","author":"HM Siragy","year":"2000","unstructured":"Siragy HM, de Gasparo M, Carey RM . Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension 2000; 35: 1074\u20131077.","journal-title":"Hypertension"},{"key":"BF1001543_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/00041552-200007000-00012","volume":"9","author":"MR Weir","year":"2000","unstructured":"Weir MR, Henrich WL . Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers. Curr Opin Nephrol Hypertens 2000; 9: 403\u2013411.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"BF1001543_CR22","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1046\/j.1523-1755.1998.00159.x","volume":"54","author":"T Ehara","year":"1998","unstructured":"Ehara T, Shigematsu H . Contribution of mast cells to the tubulointerstitial lesions in IgA nephritis. Kidney Int 1998; 54: 1675\u20131683.","journal-title":"Kidney Int"},{"issue":"1 Part 2","key":"BF1001543_CR23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1161\/01.HYP.35.1.501","volume":"35","author":"L Ghiadoni","year":"2000","unstructured":"Ghiadoni L et al. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 2000; 35 (1 Part 2): 501\u2013506.","journal-title":"Hypertension"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1001543.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1001543","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1001543.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T19:15:57Z","timestamp":1647544557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1001543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4,1]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,4,1]]}},"alternative-id":["BF1001543"],"URL":"https:\/\/doi.org\/10.1038\/sj.jhh.1001543","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4,1]]},"assertion":[{"value":"11 April 2003","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}